Physician profile
Glenn A Davis
NPI 1740275858
$4,266.49
in general payments reported to CMS, 2019-2025
32 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $597 · 2021: $864 · 2022: $500 · 2023: $259 · 2024: $647 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $841.13 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $406.97 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $405.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $399.49 | 2019-2020 | |
| Abbvie INC. | $245.54 | 2021-2024 | Vraylar |
| Amgen INC. | $224.08 | 2019-2021 | |
| Pfizer INC. | $220.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.74 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $159.17 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.55 | 2020-2022 | |
| Astellas Pharma US INC | $118.23 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $117.97 | 2019-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $91.05 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $88.66 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $85.29 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $62.85 | 2019-2021 | |
| Abbott Laboratories | $32.80 | 2022-2023 | Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $30.59 | 2022 | |
| Arbor Pharmaceuticals, INC. | $30.52 | 2021 | |
| Currax Pharmaceuticals LLC | $29.93 | 2024 | Contrave |
| Genentech USA, INC. | $29.90 | 2019-2020 | |
| Amarin Pharma, INC. | $29.89 | 2019-2021 | |
| Sanofi Pasteur INC. | $27.94 | 2019 | |
| Pulmonx Corporation | $26.45 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Seqirus USA INC | $26.42 | 2019-2020 | |
| Bausch Health US, LLC | $26.31 | 2021-2022 | |
| Renalytix Ai, INC. | $16.47 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Eisai INC. | $14.53 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.38 | 2020 | |
| Almatica Pharma LLC | $11.44 | 2021 | |
| Althera Pharmaceuticals LLC | $4.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.